E-Letter to shareholders – September 2018

Results

Message from Serge Weinberg, Chairman of the Board of Directors

Serge Weinberg

Dear shareholders
We had a busy first half of the year, with the creation of a leading platform in Rare Blood Disorders, through three consecutive deals: acquiring full global rights of fitusiran, followed by the acquisitions of two biotechnology companies, Bioverativ and Ablynx.
These operations not only allow us to build a leadership position in Rare Blood Disorders but also further strengthens our Research & Development pipeline...

 

Interview with Olivier Brandicourt, CEO

Olivier Brandicourt

What are the key highlights of the second quarter of 2018?
In the second quarter, we achieved significant milestones in building our new Rare Blood Disorder franchise and internalizing the innovative Nanobody® platform from Ablynx, as we finalized its acquisition in June...
Can you tell us more about the contribution of Dupixent® to the performance of Sanofi?
Dupixent® generated sales of €176M in the second quarter of 2018 compared to €26M in the second quarter of 2017...
Can you comment on the recent and upcoming changes at the Executive Committee level?
We announced important changes in the Executive Committee...

Second quarter 2018 results

Second Quarter 2018 Results 

Company sales stable (at CER) in the second quarter
In the second quarter of 2018, company sales were €8,176M, down 5.7% on a reported basis. Exchange rate movements had a negative effect of 5.8 percentage points. At CER, company sales increased 0.1%. They were down 2.5% at CER/CS.
Strong contributions from Specialty Care and Emerging Markets
The contribution to company sales from Specialty Care, Emerging Markets and Consumer Healthcare compensated for the decline of the Diabetes & Cardiovascular, Established Products and Vaccines franchise.

News

Global Business Units

Global Business Units 

Sanofi to refocus two Global Business Units (GBUs)
Sanofi will create a new Primary Care GBU that combines the product portfolios of the existing Diabetes and Cardiovascular (DCV) GBU with Established Products. The new Primary Care unit will focus exclusively on mature markets.
Sanofi will create a second new GBU called China & Emerging Markets. This business will focus on the unique characteristics and tremendous growth opportunities in emerging markets...

More news

  • Cablivi™ approved in the European Union
  • Divestiture of Zentiva
  • Sanofi releases its 2017 Integrated Report

Governance

Finance – Retirement of Jérôme Contamine and appointment of Jean-Baptiste Chasseloup de Chatillon

  • Jérôme Contamine, Executive Vice-President, Chief Financial Officer, will retire on September 30, 2018, after having served Sanofi for more than nine years.
  • Jean-Baptiste Chasseloup de Chatillon will succeed him starting October 1, 2018 and will be a member of the Executive Committee.

Human Ressources – Retirement of Roberto Pucci and appointment of Caroline Luscombe

  • Roberto Pucci, Executive Vice President, Human Resources, will retire end of December 2018 after having served Sanofi for more than nine years.
  • Caroline Luscombe will succeed him from October 1, 2018 and will be a member of the Executive Committee.

Primary Care – Departure of Stefan Oelrich and appointment of Dieter Weinand

  • Stefan Oelrich, Executive Vice President, DCV, will leave Sanofi and join Bayer AG as head of the Pharmaceuticals division.
  • Sanofi appoints Dieter Weinand as Executive Vice President and member of the Executive Committee (as of November 1, 2018) to lead the new Primary Care GBU.

Event

Visit of Sanofi Pasteur’s Marcy l’Etoile site « Campus Mérieux »

Annual General Meeting 2018

On June 26, 2018, the Shareholders Committee visited the Sanofi Pasteur site of Marcy l'Étoile in the Lyon region, a center of scientific and industrial expertise for the production of vaccines that are exported worldwide. The Shareholders Committee and Investor Relations team were welcomed by Alain Louvel, Deputy Site Head, and members of the site’s leadership team and had the opportunity to visit the biologics' production and quality control buildings.

Focus

The digital revolution

An exciting opportunity for the healthcare sector
In the past decade, the pace of technological change has been accelerating. The digital revolution offers tremendous opportunity for tomorrow’s medical landscape. As technology meets biology, we develop new insights into disease treatment.
Digital solutions offer new advances in care that improve the patient experience. Digital touches all areas of our business and is making us rethink and adapt our model.

Shareholder information

Salon Actionaria 2018

Salon Actionaria 2018

Save the date for Salon Actionaria 2018 
The Sanofi Investor Relations team will be happy to welcome you at the 21th edition of Actionaria, Europe’s largest exhibition for individual shareholders, on November 22 & 23, 2018 at the Palais des Congrès de Paris 2, Place de la Porte Maillot - 75017 Paris.
Come and join us at Espace “Grandes Cap”, Level 2, from 1:00 pm to 8:30 pm CET on Thursday and from 9:30 am to 7:00 pm CET on Friday.

Share performance in Paris

On June 1, 2018, Sanofi had a market capitalization of more than €83bn.

Calendar

Discover here the Sanofi upcoming shareholder and investor events

Contact the Individual Shareholder Relations team

54 rue La Boétie
75008 Paris FRANCE

France +33 800 075 876 • individualshareholders@sanofi.com

United States +1 888 516 3002